Novo Nordisk’s market value plummeted by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO. The company slashed its 2025 sales growth outlook due to lower expectations in the U.S. market, particularly for Wegovy and Ozempic. Doustdar faces the urgent challenge of reviving U.S.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets